P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial
Paul Y. Kwo(Palo Alto University), Barbara Haber(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brian L. Pearlman(Atlanta Medical Center), Marı́a Buti(Vall d'Hebron Hospital Universitari), J. Vireling(Baylor College of Medicine), Lawrence Serfaty(Inserm), Cheng‐Yuan Peng(China Medical University), Michael Robertson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jacqueline Gress(Merck & Co., Inc., Rahway, NJ, USA (United States)), Li-Wei Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), E. Gane, Janice Wahl, Paul Stryszak(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen Shafran(University of Alberta), Emily Barr(University at Buffalo, State University of New York)
Cited by 39
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
|The Lancet|2008|708
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664